The US Sepsis Diagnostics Market was valued at $255.5 Million in 2024 and projected to reach to $367.6 Million by 2029, representing a compound annual growth rate of 7.6%. The US sepsis diagnostics market is poised for sustained growth driven by increasing sepsis incidence, heightened clinical awareness of early detection benefits, and continuous innovation in diagnostic technologies.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
The US sepsis diagnostics market is valued at $255.5 million in 2024 and is projected to reach $367.6 million by 2029, representing a robust CAGR of 7.6% over the forecast period.
Increasing hospital admissions for sepsis across US healthcare facilities are driving demand for rapid and accurate diagnostic solutions to improve patient outcomes and reduce mortality rates.
Adoption of advanced molecular and immunological testing technologies in US hospitals is accelerating, enabling faster sepsis detection and more precise pathogen identification for targeted treatment.
The US healthcare system's emphasis on early diagnosis and infection control protocols is strengthening the adoption of sepsis diagnostic tools across clinical laboratories and intensive care units.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | POINT-OF-CARE TESTS (Test Type) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 7% from 2024 to 2029 |
| Largest Segment | BLOOD CULTURE (Technology) |
| Market Size Base Year (Billions) | ~USD 0.63 (2024) |
| Revenue Forecast (Billions) | ~USD 0.89 (2029) |
| Segments Covered | Technology, Product, Method, Pathogen Type, Type, Test Type, End User |
7 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CEPHEID INC. | United States | Private Company | GeneXpert instruments and Xpert test cartridges,SmartCycler system and associated reagents,Collaborative and specialized assays (e.g., TB, Ebola, USPS BDS), |
| NANOSPHERE, INC | United States | Private Company | Infectious disease molecular assays,Pharmacogenetic and human genetic assays,Protein and ultra-sensitive multiplex assays, |
| TOSOH CORPORATION | Japan | Public Company | Basic chemicals and chlor-alkali (caustic soda, VCM, EDC, sodium bicarbonate),Polymers and petrochemicals (PE, EVA, PVC pastes, synthetic rubber, functional polymers),Advanced materials (battery materials, quartzware, silica glass, thin films, zeolites, zirconia), |
| BIOMÉRIEUX | France | Public Company | Clinical microbiology (ID/AST, blood culture, culture media),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS, EMAG),Immunoassay and sepsis markers (VIDAS, Hybiome CLIA), |
| BECTON, DICKINSON AND COMPANY | United States | Public Company | Medical Essentials (syringes, needles, vascular access, sharps, basic disposables),Connected Care (infusion, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery systems), |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and related tools),Life Sciences (instruments, genomics, and reagents),Diagnostics (clinical instruments and consumables), |
| T2 BIOSYSTEMS, INC. | United States | Public Company | T2Dx instrument,T2Candida panel,T2Bacteria panel, |
| DIASORIN S.P.A. | Italy | Public Company | Immunodiagnostics – Infectious & Gastrointestinal Diseases, Hepatitis & Retroviruses,Immunodiagnostics – Endocrinology & Metabolic Disorders,Tumor Markers and Oncology Assays, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| BRUKER CORPORATION | United States | Public Company | BSI BioSpin (NMR/EPR and preclinical imaging),BSI CALID (mass spectrometry and molecular diagnostics),BSI Nano (X-ray, AFM, electron microscopy tools), |
| QUIDELORTHO CORPORATION | United States | Public Company | Labs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care, |
| SYSMEX CORPORATION | Japan | Public Company | Hematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx),Coagulation systems and reagents,Blood gas, electrolyte, and urinalysis analyzers, |
| ABBOTT LABORATORIES | United States | Public Company | Medical Devices,Diagnostic Products,Nutritional Products, |
| SIEMENS HEALTHINEERS | Germany | Public Company | Imaging,Diagnostics,Varian (Oncology), |
| QIAGEN N.V. | Netherlands | Public Company | Sample technology consumables (nucleic acid stabilization/purification),Immune response and infectious disease assays (incl. TB IGRA),Oncology and sexual/reproductive health assays, |
| SEEGENE, INC. | South Korea | Public Company | Respiratory disease detection,Gastrointestinal disease detection,STI and HPV detection, |
| PHC HOLDINGS CORPORATION | Japan | Public Company | Diabetes Management,Healthcare Solutions (EMR, receipt, pharmacy, wellness),Diagnostic and Life Sciences Equipment, |
Cepheid Inc. is a private molecular diagnostics company founded in 1996 in the United States with 1,700 employees. The company develops and manufactures diagnostic systems and tests.
Nanosphere, Inc. is a private diagnostic company founded in 1998 in the United States with 148 employees. The company focuses on molecular diagnostic technologies.
Tosoh Corporation is a Japanese public company founded in 1935 with 14,850 employees. The company operates across multiple business segments including diagnostics and healthcare products.
bioMérieux is a French public company founded in 1963 with 14,894 employees. The company specializes in in vitro diagnostics for infectious diseases and industrial microbiology.
Becton, Dickinson and Company is a United States public company founded in 1897 with 72,000 employees. The company is a global medical technology manufacturer producing diagnostic systems, devices, and reagents.
Danaher Corporation is a United States public company founded in 1969 with 59,000 employees. The company operates a diversified portfolio of businesses including diagnostics and life sciences.
T2 Biosystems, Inc. is a United States public company founded in 2006 with 113 employees. The company develops rapid diagnostic technologies for infectious diseases.
DiaSorin S.p.A. is an Italian public company founded in 1968 with 3,242 employees. The company manufactures and distributes in vitro diagnostic products.
Thermo Fisher Scientific Inc. is a United States public company founded in 1956 with 125,000 employees. The company is a global leader in serving science with laboratory equipment, reagents, and diagnostic solutions.
Bruker Corporation is a United States public company founded in 1960 with 11,085 employees. The company manufactures scientific instruments and analytical systems for research and diagnostics.
Qiagen N.V. is a Netherlands public company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics and sample preparation technologies.
QuidelOrtho Corporation is a United States public company founded in 1979 with 6,500 employees. The company develops and manufactures rapid diagnostic tests and point-of-care solutions.
Sysmex Corporation is a Japanese public company founded in 1968 with 10,861 employees. The company manufactures and sells in vitro diagnostic systems and reagents.
Siemens Healthineers is a German public company founded in 1896 with 72,369 employees. The company develops and manufactures diagnostic imaging, laboratory diagnostics, and point-of-care testing systems.
QIAGEN N.V. is a Netherlands public company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics and sample preparation technologies.
Seegene, Inc. is a South Korean public company founded in 2000 with 216 employees. The company develops and manufactures molecular diagnostic products and multiplex PCR technologies.
PHC Holdings Corporation is a Japanese public company founded in 1948 with 8,647 employees. The company manufactures and sells medical devices and diagnostic equipment.
The US sepsis diagnostics market is valued at $255.5 million in 2024 and is expected to grow to $367.6 million by 2029.
The US sepsis diagnostics market is growing at a compound annual growth rate (CAGR) of 7.6% from 2024 to 2029.
Growth in the US is driven by increasing sepsis incidence, regulatory support, improved reimbursement, technological advances in molecular diagnostics, and hospital emphasis on early detection and patient outcomes.
The US market features blood culture systems, biomarker-based assays, multiplex PCR platforms, immunological tests, and point-of-care testing solutions integrated into intensive care units.
The US market includes established diagnostic manufacturers, hospital laboratory providers, and emerging biotech companies developing innovative sepsis detection and identification platforms.
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the sepsis diagnostics market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the sepsis diagnostics market. The primary sources from the demand side include OEMs, private and contract testing organizations and service providers, among others. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.

To know about the assumptions considered for the study, download the pdf brochure
In this report, the global sepsis diagnostics market size was arrived at by using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the sepsis diagnostics products business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and key marketing executives.
To calculate the global market value, installation/volume consumption of sepsis diagnostic products were calculated. This process involved the following steps:

During preliminary secondary research, the total sales revenue of sepsis diagnostics was estimated and validated at the regional and country level, triangulated, and validated to estimate the global market value. This process involved the following steps:

To know about the assumptions considered for the study, Request for Free Sample Report
After arriving at the overall market size from the market size estimation process explained above, the global sepsis diagnostics market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the sepsis diagnostics market was validated using both top-down and bottom-up approaches.
Sepsis is a life-threatening condition caused by pathogen infection. It develops when chemicals released into the bloodstream to fight the infection trigger inflammatory responses throughout the body. This is a three-stage syndrome—from sepsis to severe sepsis and septic shock. Septic shock is the last stage that results in extremely low blood pressure and a lack of response to normal fluid replacement. Inflammation leads to multi-organ failure; progress to septic shock could lead to death.
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global sepsis diagnostics market report:
Full forecast, segment splits, and company analysis for all Sepsis Diagnostics Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report